Welcome to our dedicated page for Palisade Bio SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palisade Bio, Inc. (Nasdaq: PALI) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-assisted summaries to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on autoimmune, inflammatory, and fibrotic diseases, Palisade Bio uses SEC filings to describe its development of once-daily, oral PDE4 inhibitor prodrugs, capital-raising activities, and corporate governance matters.
Through registration statements such as Form S‑1, investors can review detailed information about Palisade Bio’s business, risk factors, and public offerings of common stock and pre-funded warrants. These documents outline how the company intends to finance its clinical programs, including the advancement of its lead candidate PALI-2108 for ulcerative colitis and fibrostenotic Crohn’s disease. AI tools on this page can highlight key sections, such as use of proceeds, dilution, and summary business descriptions.
Current reports on Form 8‑K provide timely updates on material events. Recent 8‑Ks discuss topics such as Nasdaq minimum bid price compliance, the adoption and later termination of a Phantom Unit Plan for executives and directors, outcomes of annual meetings of stockholders, and the approval of a reverse stock split authorization within a specified ratio range. These filings also cover voting results, equity-based compensation arrangements, and other corporate actions relevant to shareholders.
Proxy statements on Schedule 14A offer further detail on director elections, auditor ratification, capital structure proposals, and special meeting agendas, including warrant-related share issuance approvals. On Stock Titan, AI-powered analysis can help users quickly identify the portions of these filings that address governance changes, executive arrangements, and share authorization requests. Together, the real-time feed of SEC documents and AI summaries enables a structured view of how Palisade Bio manages its capital structure, listing status, and development priorities for its gut-targeted PDE4 inhibitor prodrug platform.
Palisade Bio, Inc. reported interim results showing clinical progress on its lead candidate, PALI-2108, while facing tightened liquidity. The company completed dosing of 89 subjects across SAD, MAD, FE and a UC cohort in its Phase 1 study and announced positive results for the SAD/MAD/FE cohorts on May 27, 2025 and for the UC cohort on August 7, 2025. Management plans a Phase 1b cohort for fibrostenotic Crohn's disease and intends Phase 2 programs; an IND for the U.S. is anticipated in the first half of 2026.
Financially, Palisade had $5.4 million in cash and equivalents as of June 30, 2025, an accumulated deficit of $141.0 million, and recognized a net loss of $2.78 million for the quarter and $5.01 million for the six months ended June 30, 2025. The company disclosed substantial doubt about its ability to continue as a going concern for one year without additional financing. Subsequent to quarter-end, a July 2025 warrant inducement closed, generating approximately $3.9 million gross proceeds.